Deacetylation of Glutaminase by HDAC4 contributes to Lung Cancer Tumorigenesis

Int J Biol Sci. 2022 Jul 4;18(11):4452-4465. doi: 10.7150/ijbs.69882. eCollection 2022.

Abstract

Inhibiting cancer metabolism via glutaminase (GAC) is a promising strategy to disrupt tumor progression. However, mechanism regarding GAC acetylation remains mostly unknown. In this study, we demonstrate that lysine acetylation is a vital post-translational modification that inhibits GAC activity in non-small cell lung cancer (NSCLC). We identify that Lys311 is the key acetylation site on GAC, which is deacetylated by HDAC4, a class II deacetylase. Lys311 acetylation stimulates the interaction between GAC and TRIM21, an E3 ubiquitin ligase of the tripartite motif (TRIM) family, therefore promoting GAC K63-linked ubiquitination and inhibiting GAC activity. Furthermore, GACK311Q mutation in A549 cells decreases cell proliferation and alleviates tumor malignancy. Our findings reveal a novel mechanism of GAC regulation by acetylation and ubiquitination that participates in non-small cell lung cancer tumorigenesis.

Keywords: HDAC4; TRIM21; acetylation; glutaminase; non-small cell lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation
  • Carcinogenesis / genetics
  • Carcinogenesis / metabolism
  • Carcinoma, Non-Small-Cell Lung* / metabolism
  • Cell Proliferation / genetics
  • Cell Transformation, Neoplastic
  • Glutaminase / genetics
  • Glutaminase / metabolism
  • Histone Deacetylases / genetics
  • Histone Deacetylases / metabolism
  • Humans
  • Lung Neoplasms* / metabolism
  • Repressor Proteins / metabolism
  • Ubiquitination

Substances

  • Repressor Proteins
  • Glutaminase
  • HDAC4 protein, human
  • Histone Deacetylases